APA

Wynne C., Altendorfer M., Sonderegger I., Gheyle L., Ellis-Pegler R., Buschke S., Lang B., Assudani D., Athalye S. & Czeloth N. (20170310). Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects. : Expert opinion on investigational drugs.

Chicago

Wynne Christopher, Altendorfer Mario, Sonderegger Ivo, Gheyle Lien, Ellis-Pegler Rod, Buschke Susanne, Lang Benjamin, Assudani Deepak, Athalye Sandeep and Czeloth Niklas. 20170310. Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects. : Expert opinion on investigational drugs.

Harvard

Wynne C., Altendorfer M., Sonderegger I., Gheyle L., Ellis-Pegler R., Buschke S., Lang B., Assudani D., Athalye S. and Czeloth N. (20170310). Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects. : Expert opinion on investigational drugs.

MLA

Wynne Christopher, Altendorfer Mario, Sonderegger Ivo, Gheyle Lien, Ellis-Pegler Rod, Buschke Susanne, Lang Benjamin, Assudani Deepak, Athalye Sandeep and Czeloth Niklas. Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects. : Expert opinion on investigational drugs. 20170310.